Plocabulin is under clinical development by Pharma Mar and currently in Phase I for Fallopian Tube Cancer. According to GlobalData, Phase I drugs for Fallopian Tube Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Plocabulin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Plocabulin overview

Plocabulin (PM-184, PM-060184) is under development for the treatment of refractory advanced solid tumors including advanced gastrointestinal stromal tumor (GIST), biliary tract adenocarcinoma, thymic cancer, cervix carcinoma, epithelial ovarian cancer including primary peritoneal disease, fallopian tube carcinomas, endometrial adenocarcinomas, advanced or metastatic head and neck cancer, non-small cell lung cancer (NSCLC), germ cell tumors (GCTs), biliary tract adenocarcinoma, urothelial cancer and HER2 negative metastatic breast cancer (second line) and metastatic colorectal cancer. The drug candidate is administered. It is a marine sponge (Lithoplocamia lithistoides) derived, synthetically produced compound. It is a tubulin-binding agent. The drug candidate was under development for the treatment of hormone-receptor positive advanced breast cancer.

Pharma Mar overview

Pharma Mar discovers, develops and markets marine-derived drugs to treat cancer. The company’s marketed products include Yondelis (trabectedin) an antitumor agent indicated for the treatment of soft tissue sarcoma and relapsed ovarian cancer in combination with doxorubicin HCl liposome injection; Aplidin (plitidepsin), an anticancer agent for the treatment of multiple myeloma; and Zepzelca (lurbinectedin) for small cell lung cancer. Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. It also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus. Its development pipeline includes PM14 for solid tumors, among others. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, and the US, among others. Pharma Mar is headquartered in Madrid, Spain.

For a complete picture of Plocabulin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.